Claims for Patent: 8,071,137

Summary for Patent: 8,071,137

Title:	Method for treatment of cartilage disorders with centella extract
Abstract:	The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of Centella extract. The composition is delivered locally by parenteral administration to the affected site.
Inventor(s):	Dhanaraj; Sridevi (Raritan, NJ), Fang; Carrie H. (Pittstown, NJ)
Assignee:	Advanced Technologies and Regenerative Medicine, LLC (Raynham, MA)
Application Number:	12/059,915
Patent Claims:	1. A method of treating mammalian articular cartilage disorders, said method comprising: parenterally administering a therapeutically effective amount of a parenteral composition, said composition comprising: between about 0.001% to about 1% by weight of an extract of Centella comprising asiatic acid, madecassic acid, and asiaticoside and a parenterally acceptable carrier, wherein the composition is administered to an affected site having mammalian articular cartilage disorder. 2. The method of claim 1, wherein the articular cartilage disorder is selected from the group consisting of arthritis, osteoarthritis, inflammatory joint disease, trauma related cartilage injury, and degenerative disc disease. 3. The method of claim 1, wherein the carrier is selected from the group consisting of sterile water, sterile saline solution, albumin, gelatin, collagen, polysaccharide, monosaccharides, polyvinylpyrrolidone, polylactic acid, polyglycolic acid, polymeric amino acids, fixed oils, ethyl oleate, liposomes, glucose, sucrose, lactose, mannose, dextrose, dextran, cellulose, mannitol, sorbitol, polyethylene glycol, isopropyl alcohol, gaseous fluorocarbons, ethyl alcohol, polyvinyl pyrrolidone, propylene glycol, glycerine, gel-producing material, stearyl alcohol, stearic acid, spermaceti, sorbitan monooleate, and methylcellulose. 4. The method of claim 1, wherein the carrier comprises a colloidal dispersion system. 5. The method of claim 4, wherein the colloidal dispersion system comprises a system selected from the group consisting of nanocapsules, microspheres, beads, lipid-based systems, oil-in-water emulsions, micelles, mixed micelles, and liposomes. 6. The method of claim 1, wherein the carrier comprises a carrier selected from the group consisting of biodegradable hydrogel matrices, dendritic polymer conjugates, hyaluronic acid, and multivesicular liposomes. 7. The method of claim 1, wherein the composition also contains a solubilizing compound. 8. The method of claim 7, wherein the solubilizing compound is an amino acid compound selected from the group consisting of alanine, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, leucine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. 9. The method of claim 1, wherein the parenteral administration is selected from the group consisting of intra-articularly, intracisternally, intraocularly, intraventricularly, intrathecally, intravenously, intramuscularly, intra-peritoneally, intradermally, and intratracheally. 10. The method of claim 1, wherein the parenteral administration is intra-articularly into the synovial tissues. 11. The method of claim 1, wherein the parenteral administration is delivered intermittently. 12. The method of claim 1, wherein the parenteral administration is delivered continuously.

Details for Patent 8,071,137

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2025-09-27